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Abstract
With the long-term goal of developing receptor subtype-selective high affinity agonists for the 
uracil nucleotide-activated P2Y receptors we have carried out a series of structure activity and 
molecular modeling studies of the human P2Y2 and P2Y4 receptors. UTP analogues with 
substitutions in the 2′-position of the ribose moiety retained capacity to activate both P2Y2 and 
P2Y4 receptors. Certain of these analogues were equieffective for activation of both receptors 
whereas 2′-amino-2′-deoxy-UTP exhibited higher potency for the P2Y2 receptor and 2′-azido-
UTP exhibited higher potency for the P2Y4 receptor. 4-Thio substitution of the uracil base resulted 
in a UTP analogue with increased potency relative to UTP for activation of both the P2Y2 and 
P2Y4 receptors. In contrast, 2-thio substitution and halo- or alkyl substitution in the 5-position of 
the uracil base resulted in molecules that were 3–30-fold more potent at the P2Y2 receptor than 
P2Y4 receptor. 6-Aza-UTP was a P2Y2 receptor agonist that exhibited no activity at the P2Y4 
receptor. Stereoisomers of UTPαS and 2′-deoxy-UTPαS were more potent at the P2Y2 than P2Y4 
receptor, and the R-configuration was favored at both receptors. Molecular docking studies 
revealed that the binding mode of UTP is similar for both the P2Y2 and P2Y4 receptor binding 
pockets with the most prominent dissimilarities of the two receptors located in the second 
transmembrane domain (V90 in the P2Y2 receptor and I92 in the P2Y4 receptor) and the second 
extracellular loop (T182 in the P2Y2 receptor and L184 in the P2Y4 receptor). In summary, this 
work reveals substitutions in UTP that differentially affect agonist activity at P2Y2 versus P2Y4 
receptors and in combination with molecular modeling studies should lead to chemical synthesis 
of new receptor subtype-selective drugs.
© 2005 Elsevier Inc. All rights reserved.
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1. Introduction
Pharmacological effects of UTP (uridine 5′-triphosphate) and other uracil nucleotides on 
second messenger signaling pathways and on various tissue responses provided the initial 
indications of the existence of cell surface receptors that specifically recognize extracellular 
pyrimidines [1,2]. This concept was confirmed and extended over the past decade with the 
cloning of three different G protein-coupled receptors, the P2Y2, P2Y4 and P2Y6 receptors 
[3–6] that are activated by uracil nucleotides, and by the direct demonstration of regulated 
release of UTP from a variety of cell types [7,8].
The P2Y2 receptor is activated equipotently by both UTP and ATP (adenosine 5′-
triphosphate) and is distributed in a broad range of tissues. For example, this receptor plays 
important physiological roles in epithelial cells of the lung, gastrointestinal tract, eye, and 
other tissues [9,10]. The human P2Y4 receptor is selectively activated by UTP, and ATP is a 
potent competitive antagonist at this receptor [11]. However, the P2Y4 receptor of several 
other species is activated by both UTP and ATP [11–13], and therefore, it has proven 
difficult to differentiate the P2Y4 receptor from the P2Y2 receptor on the basis of its cognate 
agonists in, for example, rat and mouse tissues. The P2Y6 receptor is selectively activated by 
UDP (uridine 5′-diphosphate), and UTP is a weak agonist or inactive at this receptor [6,14].
The existence of three different G protein-coupled receptors that recognize uracil 
nucleotides has made difficult the pharmacological characterization or selective activation of 
these receptors in native tissues. As has proved to be the case with the P2Y receptors, i.e. 
P2Y1, P2Y11, P2Y12, and P2Y13 receptors, that are activated by adenine nucleotides, the 
metabolism and interconversion of extracellular nucleotides add complexities to the study of 
uracil nucleotide-activated receptors in native tissues [15]. For example, the ectonucleoside 
triphosphate diphosphohydrolase, NTPDase2, converts extracellular UTP to UDP [16], 
whereas ectonucleoside diphosphokinase forms UTP from UDP with the transfer of the γ-
phosphate from ATP [17].
Drugs that selectively activate or block the uracil nucleotide-activated P2Y receptors would 
provide armamentaria for circumvention of some of the problems inherent in the study of 
these physiologically important signaling proteins. However, receptor subtype-selective 
agonists or antagonists are not available for the uracil nucleotide-activated P2Y receptors 
[18]. Therefore, we have undertaken a series of pharmacological studies designed to 
systematically evaluate the effects of various modifications of the UTP structure on the 
capacity of analogues to activate the UTP-activated P2Y2 and P2Y4 receptors. Since UTP 
activates the human P2Y2 and P2Y4 receptors with similar potencies, our first goal is to 
identify substitutions in UTP analogues that differentially affect activity at either of these 
receptors. Conversely, identification of partial agonists at these receptors would open a path 
to synthesis of selective high affinity antagonists of the UTP-activated P2Y receptors in a 
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manner similar to the approach we have followed to identify a subnanomolar affinity 
antagonist for the ADP-activated P2Y1 receptor [19–21]. The results reveal encouraging 
progress in the first of these goals. We also conducted docking studies with rhodopsin-based 
homology models of the P2Y2 and P2Y4 receptors with the goal of extending insight gained 
from the empirical structure activity studies to predict optimized structures that will be 
pursued by application of new molecular syntheses. The combination of these structure 
activity analyses and molecular modeling studies provides resolution of key differences in 
the ligand binding pockets of the P2Y2 versus P2Y4 receptor that will be of heuristic 
importance for future ligand development.
2. Materials and methods
2.1. Reagents
2′-Ara-fluoro-2′-deoxyuridine (25) was purchased from R.I. Chemical, Inc. (Orange, CA). 
All other reagents and solvents were purchased from Sigma–Aldrich (St. Louis, MO).
2.2. Uracil nucleotide analogues
Most of the nucleotide analogues studied (compounds 5–10, 12–17, and 20) were purchased 
from TriLink Biotechnologies (San Diego, CA). Compound 19 was custom synthesized by 
TriLink Biotechnologies and was the gift of Dr. Victor Marquez, NCI, Frederick, MD. 
Compounds 1–4 and 3-methyluridine (26) were purchased from Sigma (St. Louis, MO). 
Compounds 21–24 were manufactured by Axxora (San Diego, CA)/Biolog Life Science 
Inst. (Bremen, Germany).
2.3. Chemical synthesis
2.3.1. Chemical methods—Methods used to prepare compounds 11 and 18 are depicted 
schematically in Fig. 1. 1H NMR spectra were obtained with a Varian Gemini 300 
spectrometer using D2O as a solvent. The chemical shifts are expressed as relative ppm from 
HOD (4.78 ppm). 31P NMR spectra were recorded at room temperature by use of Varian XL 
300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was used as an external 
standard. Purity of compounds was checked using a Hewlett-Packard 1100 HPLC equipped 
with a Luna 5µ RP-C18(2) analytical column (250 mm × 4.6 mm; Phenomenex, Torrance, 
CA). System A—linear gradient solvent system: 5 mM TBAP-CH3CN from 80:20 to 40:60 
in 20 min, then isocratic for 2 min; the flow rate was 1 mL/min. System B—linear gradient 
solvent system: 10 mM TEAA-CH3CN from 100:0 to 90:10 in 20 min, then isocratic for 
2min; the flow rate was 1 mL/min. Peaks were detected by UV absorption with a diode array 
detector. All derivatives tested for biological activity showed >99% purity in the HPLC 
systems. High-resolution mass measurements were performed on Micromass/Waters LCT 
Premier Electrospray Time of Flight (TOF) mass spectrometer coupled with a Waters HPLC 
system. Purification of the nucleotide analogues for biological testing was carried out on 
(diethylamino)ethyl (DEAE)-A25 Sephadex columns with a linear gradient (0.01–0.5 M) of 
0.5 M ammonium bicarbonate as the mobile phase. Compounds 27 and 28 were additionally 
purified by HPLC using system C (10 mM TEAA-CH3CN from 100:0 to 90:10 in 30 min, 
then isocratic for 2 min; the flow rate was 2 mL/min) with a Luna 5µ RP-C18(2) 
semipreparative column (250 mm × 10.0 mm; Phenomenex, Torrance, CA).
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2.3.2. General procedure for preparation of nucleoside 5′-triphosphate 
(compound 18)—3-Methyluridine (26) (25 mg, 0.10 mmol) and Proton Sponge (31 mg, 
0.15 mmol) were dried for several hours in high vacuum and then dissolved in trimethyl 
phosphate (1 mL). After cooling the solution at 0 °C, phosphorous oxychloride (0.02 mL, 
0.19 mmol) was added. The mixture reaction was stirred at 0 °C for 2 h. A solution of 
tributylammonium pyrophosphate (303 mg, 0.64 mmol) and tributylamine (0.09 mL, 0.39 
mmol) in DMF (1 mL) was added and stirring was continued at 0 °C for additional 20 min. 
Five milliliters of 0.2 M triethylammonium bicarbonate (TEAB) solution was added, and the 
reaction mixture was stirred at room temperature for 45 min. Analysis of the reaction 
mixture by analytical HPLC (System A) indicated the formation of three compounds, the 
corresponding nucleotide mono-, di-, and triphosphates. The mixture was subsequently 
frozen and lyophilized, and the residue was purified by Sephadex-DEAE A-25 resin ion-
exchange column chromatography and when was necessary (compounds 27 and 28) by 
semipreparative HPLC as described above. The corresponding nucleotide mono-, di-, and 
triphosphates were collected, frozen, and lyophilized as the triethylammonium or 
ammonium salts. (2′R,3′R,4′S,5′R)-1-(3′,4′-dihydroxy-5′-phosphoryloxymethyltetrahydro-
furan-2′-yl)-3-methyl-1H-pyrimidine-2,4-dione, triethylammonium salt (27) was obtained as 
a white solid (6 mg, 11%). 1H NMR (D2O) δ 8.06 (d, J = 8.4 Hz, 1H), 6.04 (d, J = 8.1 Hz, 
1H), 6.02 (d, J = 4.2 Hz, 1H), 4.37 (m, 2H), 4.28 (m, 1H), 4.07 (m, 2H), 3.30 (s, 3H); 31P 
NMR (D2O) δ 1.88; HRMS m/z found 337.0404 (M − H+)−. C10H14N2O9P requires 
337.0437; HPLC (System A) 7.6 min (99%), (System B) 11.5 min (99%). (2′R,3′R,4′S,
5′R)-1-(3′,4′-dihydroxy-5′-diphosphoryloxymethyltetrahydro-furan-2′-yl)-3-methyl-1H-
pyrimidine-2,4-dione, triethylammonium salt (28) was obtained as a white solid (1 mg, 
1%). 1H NMR (D2O) δ 8.01 (d, J = 7.8 Hz, 1H), 6.05 (d, J = 8.1 Hz, 1H), 6.01 (d, J = 3.6 
Hz, 1H), 4.41 (m, 2H), 4.27 (m, 3H), 3.31 (s, 3H); 31P NMR (D2O) δ −8.68, −11.32 (d, J = 
21.4 Hz); HRMS m/z found 417.0116 (M − H+)−. C10H15N2O12P2 requires 417.0100; HPLC 
(System A) 14.3 min (99%), (System B) 12.4 min (99%). (2′R,3′R,4′S,5′R)-1-(3′,4′-
dihydroxy-5′-triphosphoryloxymethyl-tetrahydro-furan-2′-yl)-3-methyl-1H-pyrimidine-2,4-
dione, ammonium salt (18) was obtained as a white solid (8 mg, 15%). 1H NMR (D2O) δ 
7.98 (d, J = 8.1 Hz, 1H), 6.02 (m, 2H), 4.44 (m, 1H), 4.40 (m, 1H), 4.28 (m, 3H), 3.29 (s, 
3H); 31P NMR (D2O) δ −6.64 (d, J = 20.2 Hz), −10.88 (d, J = 19.5 Hz), −21.91 (t, J = 20.2 
Hz); HRMS m/z found 496.9750 (M − H+)−. C10H16N2O15P3 requires 496.9764; HPLC 
(System A) 18.3 min (99%), (System B) 13.5 min (99%).
(2′R,3′S,4′S,5′R)-1-(3′-Fluoro-4′-hydroxy-5′-triphosphoryloxymethyl-tetrahydro-furan-2′-
yl)-1H-pyrimidine-2,4-dione, ammonium salt (11). Compound 11 (29 mg, 26%) was 
obtained as a white solid from 2′-ara-fluoro-2′-deoxyuridine (25) following the general 
procedure for 18. 1H NMR (D2O) δ 7.93 (d, J = 8.1 Hz, 1H), 6.34 (d, J = 15.6 Hz, 1H), 5.94 
(d, J = 8.1 Hz, 1H), 5.24 (d, J = 51.6 Hz, 1H), 4.60 (d, J = 19.5 Hz, 1H), 4.25 (m, 3H); 31P 
NMR (D2O) δ −9.86, −11.46 (d, J = 19.6 Hz), −23.05; HRMS m/z found 484.9576 (M − 
H+)−. C9H13N2O14FP3 requires 484.9564; HPLC (System A) 19.0 min (99%), (System B) 
11.6 min (99%).
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2.4. Assay of P2Y2 and P2Y4 receptor-stimulated phospholipase C activity
Stable cell lines expressing the human P2Y2 receptor or the human P2Y4 receptor in 
1321N1 human astrocytoma cells were generated as previously described in detail [14]. 
Agonist-induced [3H]inositol phosphate production was measured in 1321N1 cells grown to 
confluence on 48-well plates. Twelve hours before the assay, the inositol lipid pool of the 
cells was radiolabeled by incubation in 200 µL of serum-free inositolfree Dulbecco’s 
modified Eagle’s medium, containing 0.4 µCi of myo-[3H]inositol. No changes of medium 
were made subsequent to the addition of [3H]inositol. On the day of the assay, cells were 
challenged with 50 µL of the five-fold concentrated solution of receptor agonists in 200 mM 
Hepes, pH 7.3, containing 50 mM LiCl for 20 min at 37 °C. Incubations were terminated by 
aspiration of the drug-containing medium and addition of 450 µL of ice-cold 50 mM formic 
acid. After 15 min at 4 °C, samples were neutralized with 150 µL of 150 mM NH4OH. 
[3H]Inositol phosphates were isolated by ion exchange chromatography on Dowex AG 1-X8 
columns as previously described [22].
2.5. Data analyses
Agonist potencies (EC50 values) were obtained from concentration– response curves by 
non-linear regression analysis using the GraphPad software package Prism (GraphPad, San 
Diego, CA). All experiments were performed in triplicate assays and repeated at least three 
times. The results are presented as mean ± S.E.M. from multiple experiments or in the case 
of concentration effect curves from a single experiment carried out with triplicate assays that 
were representative of results from multiple experiments.
2.6. Reconstruction of the binding pocket model
The reconstruction of the P2Y2 and P2Y4 receptors around UTP was performed with the 
InducedFit module of the Prime 1.2 homology modeling program (Schrödinger, LLC). The 
calculation was restricted to the residues located within 5 Å of the ligand.
2.7. Conformational analysis of UTP inside the putative binding pocket
A conformational analysis of UTP in the binding pockets of the P2Y2 and P2Y4 receptors 
was performed by means of the mixed MCMM/LMCS sampling method as implemented in 
Macro-Model 9.0 [23] (Schrödinger, LLC). The approach combines the Monte Carlo 
Multiple Minimum (MCMM) [24] and the low-mode conformational search (LMCS) [25]. 
All of the rotatable bonds of the ligand, as well as the ligand itself as a single body, were 
subjected to Monte Carlo driven rotations and translations during the conformational search. 
The search was performed on the ligand and the residues located within 5 Å of the ligand, 
while the remaining residues were conformationally frozen. The calculations were 
conducted with the MMFFs force field [26], using water as implicit solvent (GB/SA model 
[27] as implemented in MacroModel [23]) and a molecular dielectric constant of 1. The 
Polak-Ribier Conjugate Gradient was used for the energy minimizations with a convergence 
threshold of 0.05 kJ/mol/Å.
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Synthetic methods for the preparation of nucleoside 5′-triphosphate derivatives 11 and 18 
from the nucleosides of 25 and 26, respectively, are shown in Fig. 1. The classical 
phosphorous oxychloride method was used for the synthesis of both derivatives [28,29]. The 
5′-mono (27) and diphosphate (28) derivatives of 26 were also isolated as side products.
3.2. Pharmacological assays and structure activity relationships
The human P2Y2 and P2Y4 receptors were stably expressed in 1321N1 human astrocytoma 
cells using retroviral vectors as previously described [14]. Agonist-promoted activation of 
phospholipase C (PLC) was assessed in these two stable cell lines by quantification of the 
accumulation of [3H]inositol phosphates as described in Section 2. UTP markedly 
stimulated [3H]inositol phosphate accumulation to similar levels in P2Y2 versus P2Y4 
receptor-expressing cells. Similar EC50 values also were observed for UTP (1) for activation 
of the two receptors (Fig. 2 and Table 1). ATP (2) was two-fold less potent than UTP at the 
human P2Y2 receptor, and CTP (3a) and GTP (3b) were only weakly active at this subtype. 
Both nucleotides were previously shown to be antagonists at the human P2Y4 receptor [11].
Given the similar activities of UTP at the P2Y2 versus P2Y4 receptor, we compared the 
activities of a series of ribose-modified UTP analogues (4–11) for activation of the two 
receptor types. Although less potent than UTP in most cases, all 2′-substituted molecules 
retained capacity to maximally stimulate both receptors in the test system used. Whereas 
similar potencies were observed for the 2′-O-methyl-substituted (5) and 2′-fluoro-substituted 
(9) molecules at the P2Y2 versus P2Y4 receptors (Table 1), differential effects on potencies 
at the two receptors were observed with 2′-amino (7) and 2′-azido (8) substitutions (Fig. 2 
and Table 1). That is, the potency of 2′-amino-2′-deoxyuridine-5′-triphosphate (7) was 
unchanged from UTP at the P2Y2 receptor but was 16-fold less at the P2Y4 receptor. 
Conversely, 2′-azido-substitution in 8 resulted in a greater decrease in potency at the P2Y2 
receptor than at the P2Y4 receptor. Interestingly, existence of the 2′-hydroxyl of UTP in the 
arabino configuration in 10 resulted in a molecule that exhibits similar potency to UTP at the 
P2Y2 receptor but 10-fold reduced potency at the P2Y4 receptor. The only 3′-substituted 
molecule, 3′-O-methyluridine-5′-triphosphate (6), tested was inactive at both P2Y2 and 
P2Y4 receptors.
Uracil-substituted UTP analogues (12–20) also were examined. Modification of UTP with a 
thio moiety in the 4 position in 16 resulted in an analogue that was two-fold and three-fold 
more potent than UTP at the P2Y2 and P2Y4 receptors, respectively (Fig. 3 and Table 1). In 
contrast, 2-thio-substitution in 15 resulted in a molecule that was at least as potent as UTP at 
the P2Y2 receptor and 5-fold less potent at the P2Y4 receptor. Halo- or alkyl substitution in 
the 5-position of the base (12–14) resulted in molecules 3–10-fold more potent at the P2Y2 
receptor than the P2Y4 receptor. Aza-substitution in the 6-position in 17 decreased potency 
at the P2Y2 receptor and resulted in an analogue that was inactive at the P2Y4 receptor. A 
decrease in P2Y2 receptor potency and complete loss of activity at the P2Y4 receptor also 
occurred with replacement of uracil with a pyrimidinone ring moiety, i.e. zebularine-5′-
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triphosphate [30]. Conversely, attenuated agonist activity was observed at the P2Y2 and 
P2Y4 receptors with pseudouridine-5′-triphosphate (20), in which the base moiety is 
replaced with a reoriented uracil ring.
Phosphate side chain modification as phosphothioates was examined in the stereoisomers of 
UTPαS and 2′-deoxy-UTPαS (21–24). These phosphate side chain modifications decreased 
agonist potency by approximately two orders of magnitude. Both stereoisomers of UTPαS 
(21, 22) were approximately fivefold more potent at the P2Y2 receptor than the P2Y4 
receptor (Fig. 4 and Table 1). The R-configuration was favored by both receptors by 
approximately three-fold over the S-isomer. Rp-2′-deoxy-UTPαS (23), although displaying a 
relatively large standard error, was a full agonist at the P2Y2 receptor and inactive at the 
P2Y4 receptor. Sp-2′-deoxy-UTPαS (24) was inactive at both the P2Y2 and P2Y4 receptors.
3.3. Flexible docking of UTP into putative binding pockets of the P2Y2 and P2Y4 receptors
We recently proposed, supported by experimental data, a hypothetical binding mode of 
nucleotides within P2Y receptors of subgroup A (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) 
[31,32]. Briefly, the cognate agonist nucleotide of each of these receptors is accommodated 
in the cavity defined by the third, sixth, and seventh transmembrane domains (TM) and the 
second extracellular loop (EL2). The ribose moiety of agonists is located between TM3 and 
TM7, with the negatively charged phosphate groups pointing toward TM6 and the 
nucleobase pointing toward TM1 and TM2.
Our previous success in identification of new receptor-selective high affinity agonists and 
antagonists of the P2Y1 receptor [19–21,33] was driven in part by a close interplay of 
structure activity analyses, rational new drug syntheses, and molecular modeling of the 
P2Y1 receptor binding site. Thus, we have carried out new modeling studies as described in 
Section 2 to further refine insight into the binding pocket of the P2Y2 and P2Y4 receptors. 
Our previously published binding mode [31,32] was utilized to position UTP in the putative 
binding pockets of the unoccupied P2Y2 and P2Y4 receptors. These respective binding 
pockets then were reconstructed around docked UTP by means of homology modeling under 
conditions that allowed the receptors to adapt to the presence of ligand. We subsequently 
performed a concerted conformational analysis of UTP and the surrounding residues, 
exploring simultaneously the flexibility of the ligand and the receptors. To facilitate the 
comparison among receptors, throughout this paper we use the GPCR residue indexing 
system, as explained in detail elsewhere [31].
The putative nucleotide binding pockets of the P2Y2 and P2Y4 receptors are highly 
conserved and, not surprisingly, the results of our docking experiments indicated very 
similar binding modes of UTP within both receptors (Fig. 5). The most prominent 
dissimilarities between the putative UTP binding pockets in the P2Y2 and P2Y4 receptors 
were found in residues located in TM2 (V90(2.61) in the P2Y2 receptor corresponding to 
I92(2.61) in the P2Y4 receptor) and a residue in EL2 (T182 in the P2Y2 receptor 
corresponding to L184 in P2Y4 receptor). Both of these non-conserved residues are located 
in proximity to the uracil moiety of UTP, and their presence results in an apparently smaller 
binding pocket of the P2Y4 receptor for the cognate agonist.
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The docking models suggested other ligand recognition elements. In agreement with 
observations for the P2Y1 receptor [31,32], the triphosphate moiety of UTP is putatively 
coordinated by three conserved cationic residues (Fig. 5). These residues, all Arg in P2Y2 
and P2Y4 receptors, are located in TM3 (3.29), TM6 (6.55), and TM7 (7.39). A fourth 
cationic residue located at the 7.36 position is in proximity to the ligand but, consistent with 
mutagenesis data [34], apparently does not directly interact. The NH at the 3-position of the 
uracil ring donates an H-bond to a Ser in TM7 (7.43). Alternatively, in other docking poses 
Ser(7.43) donated an H-bond to the oxygen at the 2-position of the uracil ring. This Ser 
residue is highly conserved within the P2Y family. Mutagenesis data revealed its 
fundamental role in the recognition of agonists and antagonists at the P2Y1 receptor, where 
it is probably involved in the coordination of the adenine base [31].
4. Discussion
Results from this study provide the first systematic structure activity analysis designed to 
distinguish the P2Y2 versus P2Y4 receptor selectivity of base- and ribose-modified 
analogues of UTP. The UTP receptor selectivity of molecules with phosphate side chain 
modified UTP, i.e. stereoisomers of UTPαS and 2′-deoxy-UTPαS, also was examined. 
Thio-substitution at the 4-position increases potency at both P2Y2 and P2Y4 receptors, 
whereas other base- or ribose-modifications were identified that differentially affect the 
capacity of analogues to activate the P2Y2 versus P2Y4 receptor. These results lay the 
ground-work for rational drug synthesis directed at generation of high affinity agonists that 
selectively activate either the P2Y2 receptor or P2Y4 receptor.
The P2Y2 receptor is broadly distributed in mammalian tissues, and its expression in 
epithelial cells of the lung, eye, and other tissues make it a potentially important therapeutic 
target in cystic fibrosis, eye disease, and other pathophysiologies [9,10]. Although the P2Y4 
receptor is less prominent than the P2Y2 receptor in mammals, the presence of this signaling 
protein on neuronal, vascular, and epithelial tissues also makes the P2Y4 receptor a 
potentially important drug target. Simultaneous expression of P2Y2 and P2Y4 receptors 
occurs in a number of cell types and tissues. These receptors theoretically can be delineated 
in human tissues since whereas both UTP and ATP activate the human P2Y2 receptor, only 
UTP activates the human P2Y4 receptor. However, both of these receptors are potently 
activated by ATP and UTP in rodents [11–13], and the complexities introduced by 
metabolism and interconversion of nucleotides also makes pharmacological delineation of 
the P2Y2 and P2Y4 receptors difficult in human tissues using the natural triphosphate 
agonists [15].
Few studies have addressed selectivity of synthetic nucleotide analogues at the P2Y2 and 
P2Y4 receptors, and no systematic comparison of structure activity relationships has been 
made for the P2Y2 receptor versus P2Y4 receptor using a unified assay system. Certain UTP 
analogues with substitutions in the 4-position of the base have been reported, and several of 
these, e.g. 4-SH or 4-S-hexyl analogues of UTP, retained potencies similar to UTP at the 
P2Y2 receptor [35]. To our knowledge the activities of these molecules at the P2Y4 receptor 
have not been reported. 5-Br-UTP is an agonist at both P2Y2 and P2Y4 receptors, but 
relative potencies have not been compared simultaneously in the same test system. We 
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previously directly compared at the human P2Y2 and P2Y4 receptors analogues of both UTP 
and ATP in which the ribose moiety was replaced by a fixed ring (methanocarba) system, 
i.e. a cyclopentane fused in the Northern confirmation with a cyclopropane ring [33]. (N)-
Methanocarba UTP was equipotent to UTP at both the P2Y2 and P2Y4 receptors, and this 
analogue was approximately five-fold more potent at the P2Y2 receptor than the P2Y4 
receptor. In contrast, whereas (N)-methanocarba-ATP is a very potent agonist at the human 
P2Y2 receptor, (N)-methanocarba-ATP like ATP itself is inactive at the human P2Y4 
receptor. UTPγS is a reasonably potent agonist at both P2Y2 and P2Y4 receptors [36,37]. 
Receptor activity also is retained in UTP analogues with imido- and methylene-
modifications of the phosphate side chain [18]. Finally, both diadenosine and diuridine 
polyphosphate molecules are agonists at the P2Y2 receptor with the most potent of these 
reported to be dinucleotides with four phosphates [29]. Up4U also is a potent P2Y4 receptor 
agonist.
The current structure activity studies provide encouraging new insight on agonist action at 
the P2Y2 versus P2Y4 receptors. Certain substitutions, e.g. thio-substitution in the 4-position 
of the uracil base, resulted in increases in potency at both the P2Y2 and P2Y4 receptors. 
These increases in potency are explainable on the basis of the favorable interactions that the 
sulfur atom establishes with hydrophobic residues from TM1, TM7, and EL2 in the binding 
pockets of both receptors (Fig. 5). These results strongly suggest that relative affinity can be 
retained or enhanced in future analogues modified in other positions to alter their P2Y 
receptor subtype-selectivity. The stereoselectivity in recognition of α-thiophosphate 
analogues of UTP showed a small but consistent preference at both P2Y2 and P2Y4 
receptors for the Rp isomer, which is the opposite of the diastereoselectivity found at the 
P2Y1 receptor [39].
A large number of modifications of the base or ribose moiety resulted in differential changes 
in the potency of analogues at the two receptors. Several base modifications differentially 
affected P2Y2 receptor versus P2Y4 receptor selectivity, but in all such cases P2Y2 receptor 
potency was better retained than activity at the P2Y4 receptor. As presented in Section 
3,molecular modeling indicates a larger size for the base-interacting portion of the P2Y2 
binding pocket compared to that of the P2Y4 receptor, and the observed enhancement of 
selectivity, for example, in the 5-substituted analogs is consistent with this predicted 
difference between the steric bulk tolerance of the P2Y2 receptor versus the P2Y4 receptor.
The observation that introduction of different functional groups in the 2′ position resulted in 
analogues that favored the P2Y2 receptor in some cases, e.g. 2′-amino, or the P2Y4 receptor 
in another substitution, e.g. 2′-azido, suggests both subtle differences in the binding pocket 
of these two receptors and avenues for developing analogues that favor binding to one of 
these UTP-activated receptors. The 3′-OH is intramolecularly H-bonded to the β-phosphate 
(Fig. 5) and, according to our molecular dynamics (MD) studies on the P2Y6–UDP complex 
[38], could be involved in an interaction with the cationic residues, possibly mediated by a 
water molecule. Therefore, substitutions at this position are likely to be detrimental for 
activity. Conversely, the 2′-OH apparently does not interact directly with the receptor. 
Hence, substitutions at this position are likely to be tolerated and can be exploited to 
modulate the P2Y2/P2Y4 receptor selectivity. The residues that interact directly with the 
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ribose moiety are conserved in the P2Y2 and the P2Y4 receptors (Fig. 5). Thus, the 
selectivities observed with various 2′-substituted compounds for the P2Y2 or P2Y4 receptors 
must arise from non-conserved residues located further away from the ligand that indirectly 
affect the shape of the binding pocket. Prolonged MD simulations of the receptor–ligand 
complexes in a phospholipid bilayer should reveal these residues.
In summary, these results indicate that agonist potency and P2Y2 versus P2Y4 receptor 
selectivity can be differentially modified in ribose- and base-modified analogues. Our work 
identifies molecules that may prove useful in pharmacologically distinguishing these 
receptors in complex tissues and that provide leads for rational new drug synthesis. Further 
evolution of molecular models for these two uracil nucleotide-activated receptors should 
proceed hand in hand with this novel molecule development.
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Synthetic methods for the preparation of compounds 11 and 18.
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Activation of the human P2Y2 (left panel), and P2Y4 (right panel) receptors by ribose-
modified uracil 2′-deoxynucleotide analogues containing 2′-amino (7) (▼) and 2′-azido (8) 
(▲) functionality. PLC activity was measured as described in Section 3.2 in 1321N1 human 
astrocytoma cells stably expressing the human P2Y receptors. The data are the means of 
triplicate determinations and are representative of results obtained in at least three separate 
experiments with each analog.
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Activation of the human P2Y2 (left panel), and P2Y4 (right panel) receptors by UTP (1) and 
its base-modified uracil nucleotide analogues having 5-methyl (14), 2-thio (15), and 4-thio 
(16) substitution. PLC activity was measured as described in Section 3.2 in 1321N1 human 
astrocytoma cells stably expressing the human P2Y receptors. The data are the means of 
triplicate determinations and are representative of results obtained in at least three separate 
experiments with each analog.
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Activation of the human P2Y2 (left panel), and P2Y4 (right panel) receptors by chiral α-
phosphothioate uracil nucleotide analogues 21 (▲), 22 (◆), and 23 (▼). PLC activity was 
measured as described in Section 3.2 in 1321N1 human astrocytoma cells stably expressing 
the human P2Y receptors. The data are the means of triplicate determinations and are 
representative of results obtained in three separate experiments.
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Models of the complexes formed by UTP (1) with the P2Y2 (a) and P2Y4 (b) receptors. The 
nucleotide binding pockets are highly conserved in the two receptors [23]. The only two 
sites of divergence can be found in two residues located in TM2 and EL2 (represented with 
balls and sticks) in proximity to the uracil-binding pocket. To the left of each detailed 
binding site is a schematic representation of the entire receptor structure complexed with 
UTP. In the tube representations the receptor is colored according to residue positions, with 
a spectrum of colors that ranges from red (N-terminus) to purple (C-terminus): TM1 is in 
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orange, TM2 in ochre, TM3 in yellow, TM4 in green, TM4 in cyan, TM5 in blue, TM7 in 
purple.
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